Lifeward will acquire certain IP assets and prototypes from Skelable Ltd. in exchange for $480,000 of Lifeward equity payable upon achieving milestones plus a nominal cash payment at closing. The deal includes a definitive agreement to transfer technology assets and know-how for a powered upper-body exoskeleton with AI capabilities.

The acquisition brings a key engineering team with over 60 years of combined experience in electrical, software, mechanical, and industrial design, ensuring technology transfer and continuity. The exoskeleton device integrates advanced sensing, adaptive control, and an intuitive design to support therapeutic goals like muscle re-education and improved range of motion.

This upper-limb orthotic system extends Lifeward’s ReWalk® platform into whole-body neuro-rehabilitation, leveraging shared commercial channels and enhancing relationships with PM&R physicians, neurologists, stroke specialists, and payers. The move strengthens commercial efficiency through crossover in prescriber groups and rehabilitation networks.

Lifeward targets the 245,000 annual new U.S. stroke survivors and 4.6 million prevalence-based addressable population with functional impairments. The exoskeleton is slated for commercial launch in 18–24 months pending development and regulatory approvals, with anticipated attractive gross margins and favorable unit economics.